Skip to main content

Cognitive Behavior Therapy May Be Useful for Tinnitus

25th May 2012 - A stepped care approach based on cognitive behavioral therapy appears to be suitable for widespread use by patients with tinnitus, according to results of a randomized, controlled trials in the 26th Can the number of the Lancet published."Up to 21% of adults have tinnitus, an audiological problems are more painful and debilitating," writes Rilana FF Cima, MSc, MTD, Clinical Science of Psychology, Maastricht University and the Rehabilitation of expertise and Audiology and Department of Audiology and Communication, the , Hoensbroek, Netherlands, and colleagues. "The lack of medical cures and common practices have led to expensive and prolonged treatment. Objective was to assess the effectiveness of a stepped care approach based on cognitive behavioral therapy compared with usual care in patients with tinnitus or less seriously."Between september 2007 and January 2011 in the Department of Audiology and Communication Forward, recruited scientists previously healthy Dutch speakers over 18 years of age account with untreated tinnitus.With a series of computer-generated assignment as a research assistant independently randomized patients in a 1:1 ratio for specialized treatment, focusing on cognitive behavioral therapy, retraining is sound, or receiving usual care. Randomization was stratified by severity of tinnitus and hearing, in block sizes of 4, and the patient and examiner were blinded.The primary endpoints in the study were using validated questionnaires before treatment and at 3, 8 and 12 months after the treatments given. It was health-related quality of life by the index value for the public health, the severity of tinnitus, as measured by the Tinnitus Questionnaire score, and disability, as measured by ringing Tinnitus Handicap Inventory score. The analysis was done by intention to treat multilevel mixed regression.741 patients were screened at 492 (66%) involving the investigation and treatment. The study was 12 months, 245 patients assigned intervention of cognitive behavioral therapy conferred significant improvements in all three endpoints in the study with 247 patients compared with usual care."The results are highly relevant to clinical practice because the best practices for tinnitus has not been defined, and current treatment strategies are fragmented and expensive," the authors write.Differences between groups were 0.059 for health-related quality of life (95% confidence interval [CI]: 0.025 to 0.094, Cohen's d effect size, 0.24, p = 0.0009), 8062 to the severity of tinnitus (95% CI -10.829 to -5.295, d = 0.43, p <0.0001) and -7.506 tinnitus impairment (95% CI, -4352 to -10661, d = 0, 45, p <.0001).Intervention Cognitive behavior therapy appears to be effective regardless of the first severity of tinnitus, and there were no adverse effects observed."Er, we have demonstrated the effectiveness of specialized care versus usual care, not only for the first 3 months after the initial phase of treatment but completed after the second step, an intensive treatment and 4 months without treatment," the authors conclude.Change in clinical practice and possible cure for tinnitus"Our findings may lead to a political consensus on best practices in the treatment of tinnitus result, the default options on the reference fuels lanes, and the use of standardized tinnitus evaluation and the results are more comparable."Limitations of this study include the inability to determine which of the elements of special treatment was on the overall effectiveness and possible lack of generalizability of health centers has helped some audiological rehabilitation clinic.An accompanying commentary by Berthold Langguth, MD, University of Regensburg in Germany, says that these results are not only convincing, but is also relevant for clinical practice."Although the improved care approach involved only a brief intervention for most patients, specialty care was significantly better than usual care for the entire sample," writes Dr. Langguth."For future research, we must not forget that the majority of patients with tinnitus, a cure for what should be the ultimate goal of research."The Netherlands Organisation for Health Research and Development supported this study. The study authors have NOTHING relevant financial relationships. Dr. Langguth has consulting fees, travel, housing payments, or lecture fees from AstraZeneca, Merz, Novartis, Servier, Pfizer, ANM and Magventure, research funding or equipment, Astra Zeneca, cerbomed received Magventure, American Tinnitus Association, the Deutsche Forschungsgemeinschaft and Tinnitus Research Initiative, and has patents for the treatment of tinnitus by transcranial magnetic stimulation neuronavigated with cyclobenzaprine and naltrexone.

Comments

  1. My friend's sister used to suffer frequently from panic attacks. Such the seriousness of this disorder that we had to take her to a therapist who suggested Cognitive Behavioral Therapy for her. It made him learn how to deal with situations where he use have panic attacks. Today he is a confident young lady. Read More Visit couples counseling

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n